PepGen PEPG 深 滬
已收盤 11-06 16:00:00 美东时间
2.47
+0.150
+6.47%
華盛通- 最 高2.52
- 今 開2.33
- 成交量 99.82万股
- 最 低 2.33
- 昨 收 2.32
- 總市值 1.71亿
- 52周最高 7.80
- 市盈率 靜 --
- 換手率 1.44%
- 52周最低 1.31
- 委 比 -63.67%
- 總股本 6925.95万
- 歷史最高 20.00
- 量 比 0.98
- 振 幅 8.19%
- 歷史最低 0.8801
- 每 手 1
- 風險率 1.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PepGen收跌0.42%，成交额132.94万美元
11月3日，PepGen（PEPG）收跌0.42%，报2.35美元，成交额132.94万美元，市值1.63亿美元。 行情数据 • 开盘价：2.39美元 • 最高...
11-03 07:45
PepGen收跌1.19%，成交额229.17万美元
10月27日，PepGen（PEPG）收跌1.19%，报2.49美元，成交额229.17万美元，市值1.72亿美元。 行情数据 • 开盘价：2.51美元 • 最...
10-27 06:45
PepGen收涨2.77%，成交额310.68万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:47
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
HC Wainwright & Co. Reiterates Buy on PepGen, Maintains $20 Price Target
HC Wainwright & Co. analyst Ananda Ghosh reiterates PepGen (NASDAQ:PEPG) with a Buy and maintains $20 price target.
09-09 18:14
PepGen Q2 EPS $(0.26) Beats $(0.29) Estimate
PepGen (NASDAQ:PEPG) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.29) by 10.34 percent. This is a 62.86 percent increase over losses of $(0.70) per share from the same period last year.
08-06 20:04
Kalaris Appoints Laurie Keating to Board of Directors
Kalaris Therapeutics announced the appointment of Laurie Keating to its Board of Directors, effective August 1, 2026. Keating brings extensive expertise in biotechnology, having previously served in senior roles at Alnylam Pharmaceuticals and Millennium Pharmaceuticals. Her addition is expected to support Kalaris' growth and development of treatments for retinal diseases, including the ongoing clinical trial for TH103, a potential therapy for con...
07-06 20:05
美股大行评级 | 潜在涨幅117.92%！摩根大通上调Camp4 Therapeutics目标价至9美元，维持"超配"评级
今日重点评级关注：摩根大通：上调Camp4 Therapeutics评级至"超配"，目标价从5美元升至9美元；Canaccord Genuity：维持Rhythm制药"买入"评级，目标价从143美元升至151美元
06-17 11:32
Craig-Hallum Initiates Coverage On PepGen with Buy Rating, Announces Price Target of $11
Craig-Hallum analyst Adam Vogel initiates coverage on PepGen (NASDAQ:PEPG) with a Buy rating and announces Price Target of $11.
06-16 22:33
PepGen To Highlight Data From PGN-EDODM1 Program In Poster And Late-Breaking Oral Presentation At IDMC-15
PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases,
05-21 19:04
